<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127784">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01438684</url>
  </required_header>
  <id_info>
    <org_study_id>026011- HMO-CTIL</org_study_id>
    <nct_id>NCT01438684</nct_id>
  </id_info>
  <brief_title>The Impact of RPh201 on Chronic Vegetative State (CVS): fMRI Study</brief_title>
  <acronym>RPh-in-CVS</acronym>
  <official_title>Phase 1 Study of RPh201 in Patients With Chronic Vegetative or Minimal Conscious State</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <brief_summary>
    <textblock>
      The aim is to evaluate the impact of RPh201 on brain activity in chronic vegetative state
      patients. The assessment will be done using clinical measurements and functional MRI
      studies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>consciousness level measured clinically</measure>
    <time_frame>6 months</time_frame>
    <description>Each patient will undergo a behavioral assessment (using the Coma Recovery Scale Revised) before treatment and every 2 weeks during the treatment period as well as 3 months following the end of the treatment. Complete blood counts, electrolytes, liver function tests, renal function tests and ECG will be performed every two weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional magnetic resonance imaging of cortical activity</measure>
    <time_frame>6 months</time_frame>
    <description>3 scans will be performed: before treatment, after three months of treatment and 3 months after cessation of treatment. Scanning sessions will include a hierarchical auditory paradigm, an imagery task and resting state fMRI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Chronic Vegetative State</condition>
  <arm_group>
    <arm_group_label>RPh201 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>7 patients will receive the treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non RPh201 group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 patients will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RPh201</intervention_name>
    <description>400 microliter s.c. twice a week for 3 months</description>
    <arm_group_label>RPh201 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>400 microliter Saline solution s.c. twice a week for 3 months</description>
    <arm_group_label>non RPh201 group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic vegetative state patients

        Exclusion Criteria:

          -  allergic reaction to treatment

          -  patients that can not undergo MRI

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Arik Tzukert, DMD</last_name>
    <phone>00 972 2 6776095</phone>
    <email>arik@hadassah.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hadas Lemberg, PhD</last_name>
    <phone>00 972 2 6777572</phone>
    <email>lhadas@hadassah.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Netta Levin</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Netta Levin, Md Phd</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 30, 2015</lastchanged_date>
  <firstreceived_date>September 21, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hadassah Medical Organization</investigator_affiliation>
    <investigator_full_name>Netta Levin</investigator_full_name>
    <investigator_title>Dr. Netta Levin</investigator_title>
  </responsible_party>
  <keyword>chronic vegetative state</keyword>
  <keyword>functional MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Persistent Vegetative State</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
